

Personalized Literature Report

Generated 2/4/2026

Patient Summary

40

AGE

Male

SEX

Relevant Lab Values

LDL Cholesterol: 145 mg/dL

Study Information

Untitled Study

Intervention: evolocumab (either 140 mg every 2 weeks or 420 mg monthly)

Primary Endpoint: composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization

Follow-up: 2.2 years median

Applicability Assessment

This study may not directly apply to this patient

Based on the patient's health records, the findings from this study might not be directly applicable.

Reasons

CONDITION

Patient does not have required condition: atherosclerotic cardiovascular disease

The study required patients to have atherosclerotic cardiovascular disease

MEDICATION

Patient is not on required medication: statin therapy

The study required patients to be taking statin therapy

Important: This personalized summary is based on a research study and health data. It is not medical advice. Always discuss treatment decisions with your healthcare provider. Individual results may vary from study findings.

Generated by FHIR Literature Personalization Tool